Real-time DNA test during brain surgery could help remove more cancer
NCT ID NCT07219199
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
This study tests a fast genetic test (UR-ddPCR) that checks for IDH1-mutant tumor cells in brain tissue during surgery. If the test finds leftover cancer, the surgeon can remove more tissue right away. The trial will enroll 105 adults with newly diagnosed IDH-mutant glioma at NYU Langone Health. The goal is to see if this approach improves how long patients live without their cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
New York, New York, 10016, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UR-ddPCR assay (a rapid genetic test)
What this could lead to
If successful, this test could help surgeons remove more tumor during surgery, potentially delaying cancer progression and improving survival.
What could go wrong
This is an early-stage, single-site study with only 105 participants. The test may not reliably detect all residual tumor cells, and added resection could increase surgical risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.